rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ryan Spencer

CEO and Director

Company insider

Files Form 4 as: CEO and Director, Dynavax Technologies; Director, Cidara Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
112
Buys
0
Sells
2
Bought
$0
Sold
$1.1M
Companies
2
Companies where not an officer
1
First trade
2 Jun 2019
Last trade
10 Feb 2026
Last filed
10 Feb 2026

Companies traded

Where they are an officer
Dynavax TechnologiesDirector, Officer · Biotechnology · last 10 Feb 20260 buys · 2 sells
Everywhere else they filed: board seats, 10% stakes, other companies
Cidara TherapeuticsDirector · Biotechnology · last 7 Jan 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code U—379,620filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—350,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—280,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—231,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—225,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—55,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—90,667filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—165,000filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—165,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—50,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—400,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—130,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—250,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—350,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—280,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—231,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—225,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—55,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—90,667filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—136,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Deep Track Biotechnology Master Fund, Ltd.10% owner · 10% owner at Dynavax Technologies, filing Form 4 there in the last year
Francis CanoDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
Scott Dunseth MyersDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
John L. SlebirSVP General Counsel · SVP General Counsel at Dynavax Technologies, filing Form 4 there in the last year
David F. NovackPresident & COO · President & COO at Dynavax Technologies, filing Form 4 there in the last year